Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-Tooth disease

ACS Chemical Biology

Volumn 9, Issue 11, 2014, Pages 2594-2602

  Inglese, James ^a,b   Dranchak, Patricia ^a   Moran, John J ^c   Jang, Sung Wook ^a   Srinivasan, Rajini ^c   Santiago, Yolanda ^d   Zhang, Lei ^d   Guha, Rajarshi ^a   Martinez, Natalia ^a   Macarthur, Ryan ^a   Cost, Gregory J ^d   Svaren, John ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d SANGAMO BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BRYOSTATIN; PERIPHERAL MYELIN PROTEIN 22; PROTEIN KINASE C;

ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG TARGETING; GENE LOCUS; GENETIC TRANSFECTION; GENOME; HEREDITARY MOTOR SENSORY NEUROPATHY; HIGH THROUGHPUT SCREENING; HUMAN; PROTEIN EXPRESSION; REPORTER GENE; SCHWANN CELL; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME;

CHARCOT-MARIE-TOOTH DISEASE; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS;

EID: 84914104961     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb5005492     Document Type: Article

References (44)

1. Reilly, M. M., Murphy, S. M., and Laurá, M. (2011) Charcot-Marie-Tooth disease J. Peripher. Nerv. Syst. 16, 1-14
2. Shy, M. E., Chen, L., Swan, E. R., Taube, R., Krajewski, K. M., Herrmann, D., Lewis, R. A., and McDermott, M. P. (2008) Neuropathy progression in Charcot-Marie-Tooth disease type 1A Neurology 70, 378-383
3. Patzko, A., and Shy, M. E. (2011) Update on Charcot-Marie-Tooth disease. Curr. Neurol. Neurosci. Rep. 11, 78-88.
4. Saporta, A. S., Sottile, S. L., Miller, L. J., Feely, S. M., Siskind, C. E., and Shy, M. E. (2011) Charcot-Marie-Tooth disease subtypes and genetic testing strategies Ann. Neurol. 69, 22-33
5. Murphy, S. M., Laura, M., Fawcett, K., Pandraud, A., Liu, Y. T., Davidson, G. L., Rossor, A. M., Polke, J. M., Castleman, V., Manji, H., Lunn, M. P., Bull, K., Ramdharry, G., Davis, M., Blake, J. C., Houlden, H., and Reilly, M. M. (2012) Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing J. Neurol., Neurosurg. Psychiatry 83, 706-710
6. Patel, P. I., Roa, B. B., Welcher, A. A., Schoener-Scott, R., Trask, B. J., Pentao, L., Snipes, G. J., Garcia, C. A., Francke, U., Shooter, E. M., Lupski, J. R., and Suter, U. (1992) The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A Nat. Genet. 1, 159-165
7. Timmerman, V., Nelis, E., Van Hul, W., Nieuwenhuijsen, B. W., Chen, K. L., Wang, S., Ben Othman, K., Cullen, B., Leach, R. J., and Hanemann, C. O. (1992) The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication Nat. Genet. 1, 171-175
8. Huxley, C., Passage, E., Manson, A., Putzu, G., Figarella-Branger, D., Pellissier, J. F., and Fontes, M. (1996) Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA Hum. Mol. Genet. 5, 563-569
9. Huxley, C., Passage, E., Robertson, A. M., Youl, B., Huston, S., Manson, A., Saberan-Djoniedi, D., Figarella-Branger, D., Pellissier, J. F., Thomas, P. K., and Fontes, M. (1998) Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice Hum. Mol. Genet. 7, 449-458
10. Magyar, J. P., Martini, R., Ruelicke, T., Aguzzi, A., Adlkofer, K., Dembic, Z., Zielasek, J., Toyka, K. V., and Suter, U. (1996) Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage J. Neurosci. 16, 5351-5360
11. Robertson, A. M., Perea, J., McGuigan, A., King, R. H., Muddle, J. R., Gabreels-Festen, A. A., Thomas, P. K., and Huxley, C. (2002) Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A J. Anat. 200, 377-390
12. Sereda, M., Griffiths, I., Puhlhofer, A., Stewart, H., Rossner, M. J., Zimmerman, F., Magyar, J. P., Schneider, A., Hund, E., Meinck, H. M., Suter, U., and Nave, K. A. (1996) A transgenic rat model of Charcot-Marie-Tooth disease Neuron 16, 1049-1060
13. Passage, E., Norreel, J. C., Noack-Fraissignes, P., Sanguedolce, V., Pizant, J., Thirion, X., Robaglia-Schlupp, A., Pellissier, J. F., and Fontes, M. (2004) Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease Nat. Med. 10, 396-401
14. Perea, J., Robertson, A., Tolmachova, T., Muddle, J., King, R. H., Ponsford, S., Thomas, P. K., and Huxley, C. (2001) Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A Hum. Mol. Genet. 10, 1007-1018
15. Sereda, M. W., Meyer zu Horste, G., Suter, U., Uzma, N., and Nave, K. A. (2003) Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A) Nat. Med. 9, 1533-1537
16. Lewis, R. A., McDermott, M. P., Herrmann, D. N., Hoke, A., Clawson, L. L., Siskind, C., Feely, S. M., Miller, L. J., Barohn, R. J., Smith, P., Luebbe, E., Wu, X., Shy, M. E., and Group, M. S. (2013) High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial JAMA Neurol. 70, 981-987
17. Topilko, P., Schneider-Maunoury, S., Levi, G., Baron-Van Evercooren, A., Chennoufi, A. B., Seitanidou, T., Babinet, C., and Charnay, P. (1994) Krox-20 controls myelination in the peripheral nervous system Nature 371, 796-799
18. Britsch, S., Goerich, D. E., Riethmacher, D., Peirano, R. I., Rossner, M., Nave, K. A., Birchmeier, C., and Wegner, M. (2001) The transcription factor Sox10 is a key regulator of peripheral glial development Genes Dev. 15, 66-78
19. Jones, E. A., Lopez-Anido, C., Srinivasan, R., Krueger, C., Chang, L. W., Nagarajan, R., and Svaren, J. (2011) Regulation of the PMP22 gene through an intronic enhancer J. Neurosci. 31, 4242-4250
20. Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D. T., and Austin, C. P. (2011) The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Sci. Transl. Med. 3, 80ps16
21. Jang, S. W., Lopez-Anido, C., MacArthur, R., Svaren, J., and Inglese, J. (2012) Identification of drug modulators targeting gene-dosage disease CMT1A ACS Chem. Biol. 7, 1205-1213
22. Verrier, J. D., Lau, P., Hudson, L., Murashov, A. K., Renne, R., and Notterpek, L. (2009) Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a Glia 57, 1265-1279
23. Lau, P., Verrier, J. D., Nielsen, J. A., Johnson, K. R., Notterpek, L., and Hudson, L. D. (2008) Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes J. Neurosci. 28, 11720-11730
24. Jones, E. A., Brewer, M. H., Srinivasan, R., Krueger, C., Sun, G., Charney, K. N., Keles, S., Antonellis, A., and Svaren, J. (2012) Distal enhancers upstream of the Charcot-Marie-Tooth type 1A disease gene PMP22 Hum. Mol. Genet. 21, 1581-1591
25. Weterman, M. A., van Ruissen, F., de Wissel, M., Bordewijk, L., Samijn, J. P., van der Pol, W. L., Meggouh, F., and Baas, F. (2010) Copy number variation upstream of PMP22 in Charcot-Marie-Tooth disease Eur. J. Hum. Genet. 18, 421-428
26. Zhang, F., Seeman, P., Liu, P., Weterman, M. A., Gonzaga-Jauregui, C., Towne, C. F., Batish, S. D., De Vriendt, E., De Jonghe, P., Rautenstrauss, B., Krause, K. H., Khajavi, M., Posadka, J., Vandenberghe, A., Palau, F., Van Maldergem, L., Baas, F., Timmerman, V., and Lupski, J. R. (2010) Mechanisms for nonrecurrent genomic rearrangements associated with CMT1A or HNPP: rare CNVs as a cause for missing heritability Am. J. Hum. Genet. 86, 892-903
27. Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., Dulay, G. P., Hua, K. L., Ankoudinova, I., Cost, G. J., Urnov, F. D., Zhang, H. S., Holmes, M. C., Zhang, L., Gregory, P. D., and Rebar, E. J. (2011) A TALE nuclease architecture for efficient genome editing Nat. Biotechnol. 29, 143-148
28. Carroll, D. (2014) Genome engineering with targetable nucleases Annu. Rev. Biochem. 83, 409-439
29. Toda, K., Small, J. A., Goda, S., and Quarles, R. H. (1994) Biochemical and cellular properties of three immortalized Schwann cell lines expressing different levels of the myelin-associated glycoprotein J. Neurochem. 63, 1646-1657
30. Fang, J., Qian, J. J., Yi, S., Harding, T. C., Tu, G. H., VanRoey, M., and Jooss, K. (2005) Stable antibody expression at therapeutic levels using the 2A peptide Nat. Biotechnol. 23, 584-590
31. Tannous, B. A., Kim, D. E., Fernandez, J. L., Weissleder, R., and Breakefield, X. O. (2005) Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo Mol. Ther. 11, 435-443
32. Hall, M. P., Unch, J., Binkowski, B. F., Valley, M. P., Butler, B. L., Wood, M. G., Otto, P., Zimmerman, K., Vidugiris, G., Machleidt, T., Robers, M. B., Benink, H. A., Eggers, C. T., Slater, M. R., Meisenheimer, P. L., Klaubert, D. H., Fan, F., Encell, L. P., and Wood, K. V. (2012) Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate ACS Chem. Biol. 7, 1848-1857
33. Ho, P. I., Yue, K., Pandey, P., Breault, L., Harbinski, F., McBride, A. J., Webb, B., Narahari, J., Karassina, N., Wood, K. V., Hill, A., and Auld, D. S. (2013) Reporter enzyme inhibitor study to aid assembly of orthogonal reporter gene assays ACS Chem. Biol. 8, 1009-1017
34. Inglese, J., Auld, D. S., Jadhav, A., Johnson, R. L., Simeonov, A., Yasgar, A., Zheng, W., and Austin, C. P. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries Proc. Natl. Acad. Sci. U.S.A. 103, 11473-11478
35. Thorne, N., Inglese, J., and Auld, D. S. (2010) Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology Chem. Biol. 17, 646-657
36. Chan, J. R., Phillips, L. J., and Glaser, M. (1998) Glucocorticoids and progestins signal the initiation and enhance the rate of myelin formation Proc. Natl. Acad. Sci. U.S.A. 95, 10459-10464
37. Désarnaud, F., Bidichandani, S., Patel, P. I., Baulieu, E. E., and Schumacher, M. (2000) Glucocorticosteroids stimulate the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells Brain Res. 865, 12-16
38. Ruan, B. F. and Zhu, H. L. (2012) The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development Curr. Med. Chem. 19, 2652-2664
39. Taveggia, C., Feltri, M. L., and Wrabetz, L. (2010) Signals to promote myelin formation and repair Nat. Rev. Neurol. 6, 276-287
40. Wu-Zhang, A. X. and Newton, A. C. (2013) Protein kinase C pharmacology: refining the toolbox Biochem. J. 452, 195-209
41. Pereira, J. A., Lebrun-Julien, F., and Suter, U. (2012) Molecular mechanisms regulating myelination in the peripheral nervous system Trends Neurosci. 35, 123-134
42. Samsonov, A., Zenser, N., Zhang, F., Zhang, H., Fetter, J., and Malkov, D. (2013) Tagging of genomic STAT3 and STAT1 with fluorescent proteins and insertion of a luciferase reporter in the cyclin D1 gene provides a modified A549 cell line to screen for selective STAT3 inhibitors PLoS One 8, e68391
43. Lyssiotis, C. A., Foreman, R. K., Staerk, J., Garcia, M., Mathur, D., Markoulaki, S., Hanna, J., Lairson, L. L., Charette, B. D., Bouchez, L. C., Bollong, M., Kunick, C., Brinker, A., Cho, C. Y., Schultz, P. G., and Jaenisch, R. (2009) Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4 Proc. Natl. Acad. Sci. U.S.A. 106, 8912-8917
44. Tannous, B. A. (2009) Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo Nat. Protoc. 4, 582-591